Compare iShares Core MSCI Emerging Markets ETF (IEMG) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI Emerging Markets ETF vs Marsh & McLennan Companies, Inc. — how do they compare? iShares Core MSCI Emerging Markets ETF trades at $81.4 (market cap $162.00B), while Marsh & McLennan Companies, Inc. trades at $175.76 (market cap $84.31B). The key difference: iShares Core MSCI Emerging Markets ETF is the larger of the two by market cap, and Marsh & McLennan Companies, Inc. pays a 2.24% dividend while iShares Core MSCI Emerging Markets ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI Emerging Markets ETF for 57 Days and Marsh & McLennan Companies, Inc. for 109 Days on average.
| IEMG | MRSH | |
|---|---|---|
Market Cap | $162.00B | $84.31B |
Volume | 13,446,151 | 3,948,947 |
Sector | Broad Market / Factor | Financials |
52-Week High | $86.00 | $207.02 |
52-Week Low | $64.22 | $157.32 |
Typical Hold Time | 57 Days | 109 Days |
Enterprise Value | — | $104.99B |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEMG trades at $81.40, down 0.78% with bearish technical signals from moving averages while oscillators remain neutral. The emerging markets ETF has demonstrated strong performance with 35% returns over the past year according to recent analysis, though faces competition from lower-cost alternatives. Recent news highlights emerging markets attracting record capital flows as investors diversify beyond US mega-cap technology stocks.
The outlook remains cautiously optimistic given emerging markets' recent outperformance and dollar weakness, though higher expense ratios compared to competitors and concentration in technology sectors present risks. Technical indicators suggest near-term pressure with support at $79-80 levels, while fundamental strength in emerging market growth supports longer-term potential.
Marsh (MRSH) trades at $176.67, up 1.73% today, near its consensus price target of $202.71. The stock shows a bullish technical trend with support at $174 and resistance at $178. Recent earnings beats and the acquisition of Accel Holdings highlight strong operational momentum. Revenue grew to $27.0B in 2025, with a net income margin of 14.24% and a P/E ratio of 21.57, indicating solid profitability amid moderate valuation.
The outlook remains positive with consistent earnings outperformance and strategic acquisitions driving growth. Risks include elevated debt levels and potential margin pressure. Analysts are mostly neutral (65% Hold), but the stock offers upside to the price target. Investors should weigh strong cash flow generation against macroeconomic sensitivities in the insurance sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
